Open Access Repository

The effect of disease modifying therapies on disability progression in multiple sclerosis: A systematic overview of meta-analyses


Downloads per month over past year

Claflin, SB ORCID: 0000-0001-6545-946X, Broadley, S and Taylor, BV 2019 , 'The effect of disease modifying therapies on disability progression in multiple sclerosis: A systematic overview of meta-analyses' , Frontiers in Neurology, vol. 9 , pp. 1-25 , doi: 10.3389/fneur.2018.01150.

131509 - The ef...pdf | Download (1MB)

| Preview


Background: Disease modifying therapy (DMT) efficacy trials make an essential contribution to the development of evidence-based clinical treatments and practices for people with multiple sclerosis (MS). Meta-analysis is a critical part of this process and provides a powerful tool to assess the effects of DMT on MS progression. However, although there have been several meta-analyses on the effect of DMT on MS disease progression, they often do not reach the same conclusions. Objective: Our aim was to better understand and contextualize the results of meta-analyses evaluating DMT, identify differences in methodology that might explain their differing conclusions, and highlight areas for future research that will improve our ability to develop clinical recommendations.Methods: We conducted an overview of systematic reviews with meta-analyses assessing the efficacy of DMT on disability progression in people with MS in PubMed (Medline) and the Cochrane Database of Systematic Reviews. Results: We included 22 meta-analyses in this overview: eight general (on >3 DMT), 11 specific (on ≤3 DMT), 2 that evaluated subsets, and 1 that evaluated long-term effects. We found that there is good evidence that DMT improve short-term (≤2-3 years) disability progression outcomes relative to placebo in people with relapsing-remitting MS. However, results varied substantially between meta-analyses, and there is little evidence of their efficacy in other populations or over longer periods. The relative effects of individual DMT also remain unclear. The variance in results between meta-analyses may be related to the substantial differences in inclusion criteria, which was reflected in the limited overlap in included studies, as well as the year of meta-analysis publication. Of the 123 total unique studies included in the general meta-analyses, 77 (62.6%) were included in only one meta-analysis. This incongruence was also evident in the included DMT. Six of the 16 (37.5%) DMT evaluated in the general meta-analyses were only included in one meta-analysis. Conclusions: Translating DMT efficacy studies into evidence-based clinical practice requires greater methodological consistency in meta-analyses, more data on the relative effects of DMT through head-to-head clinical trials, and better reporting of adverse events.

Item Type: Article
Authors/Creators:Claflin, SB and Broadley, S and Taylor, BV
Keywords: disability progression, disease modifying therapies, meta-analysis, multiple sclerosis, systematic review
Journal or Publication Title: Frontiers in Neurology
Publisher: Frontiers Research Foundation
ISSN: 1664-2295
DOI / ID Number: 10.3389/fneur.2018.01150
Copyright Information:

Copyright 2019 Claflin, Broadley and Taylor. Licensed under Creative Commons Attribution 4.0 International (CC BY 4.0)

Related URLs:
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page